Publications by authors named "David Wildes"

Claim this Profile
C
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, Yingyun Wang, Matthew Holderfield, David Wildes

Cancer Discov· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A neomorphic protein interface catalyzes covalent inhibition of RAS aspartic acid in tumors.
Caroline Weller, G Leslie Burnett, Lingyan Jiang, Sujata Chakraborty, Dongyu Zhang, David Wildes

Science· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers.
James Cregg, Kristof Pota, Aidan C A Tomlinson, Jason Yano, Abby Marquez, David Wildes

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.
James Cregg, Anne V Edwards, Stephanie Chang, Bianca J Lee, John E Knox, David Wildes

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards, David Wildes

Nature· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of KRAS and mTORC1 kinase is synergistic in non-small cell lung cancer.
Hidenori Kitai, Philip H Choi, Yu C Yang, Jacob A Boyer, Adele Whaley, David Wildes

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, Yingyun Wang, Matthew Holderfield, David Wildes

Cancer Discov· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Urszula N Wasko, Jingjing Jiang, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards, David Wildes

Nature· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Matthew Holderfield, Bianca J Lee, Jingjing Jiang, Aidan Tomlinson, Kyle J Seamon, David Wildes

Nature· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.
Urszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, Yingyun Wang, Bianca Lee, David Wildes

bioRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
Christopher J Schulze, Kyle J Seamon, Yulei Zhao, Yu C Yang, Jim Cregg, David Wildes

Science· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.
G Leslie Burnett, Yu C Yang, James B Aggen, Jennifer Pitzen, Micah K Gliedt, David Wildes

J Med Chem· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, David Wildes

Nat Chem Biol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, David Wildes

Nat Chem Biol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Bianca J Lee, Jacob A Boyer, G Leslie Burnett, Arun P Thottumkara, Nidhi Tibrewal, David Wildes

Nat Chem Biol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia.
Bianca J Lee, Sharmila Mallya, Nuntana Dinglasan, Amos Fung, Tram Nguyen, David Wildes

Front Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity.
Darienne R Myers, Clare L Abram, David Wildes, Amira Belwafa, Alia M N Welsh

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Elsa Quintana, Christopher J Schulze, Darienne R Myers, Tiffany J Choy, Kasia Mordec, David Wildes

Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Robert J Nichols, Franziska Haderk, Carlos Stahlhut, Christopher J Schulze, Golzar Hemmati, David Wildes

Nat Cell Biol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sampling the N-terminal proteome of human blood.
David Wildes, James A Wells

Proc Natl Acad Sci U S A· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Native state energetics of the Src SH2 domain: evidence for a partially structured state in the denatured ensemble.
David Wildes, L Meadow Anderson, Alex Sabogal, Susan Marqusee

Protein Sci· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the precision of experimentally determined protein folding rates and phi-values.
Miguel A de los Rios, B K Muralidhara, David Wildes, Tobin R Sosnick, Susan Marqusee

Protein Sci· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein folding: defining a "standard" set of experimental conditions and a preliminary kinetic data set of two-state proteins.
Karen L Maxwell, David Wildes, Arash Zarrine-Afsar, Miguel A De Los Rios, Andrew G Brown

Protein Sci· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrogen exchange and ligand binding: ligand-dependent and ligand-independent protection in the Src SH3 domain.
David Wildes, Susan Marqusee

Protein Sci· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydrogen-exchange strategies applied to energetics of intermediate processes in protein folding.
David Wildes, Susan Marqusee

Methods Enzymol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis